Drug Resistant Epilepsy Clinical Trial
Official title:
Cannabidiol (CBD) Cannabis Extract Oral Solution for Drug Resistant Pediatric Epilepsy (Expanded Access Use)
NCT number | NCT03676049 |
Other study ID # | 2017-0259 |
Secondary ID | |
Status | Available |
Phase | |
First received | |
Last updated |
This is a treatment study under an approved Expanded Use IND protocol for using Cannabidiol (CBD) Extract. CBD will be used for the treatment of 5-10 children with drug resistant epilepsy. The CBD used in this study is prepared at the University of Mississippi under approval of the National Institute on Drug Abuse (NIDA) for its preparation and FDA approval under an expanded access mechanism on a compassionate use basis. The target patient population is who would otherwise have no appropriate remaining treatment modality left. These are patients for whom the risks of a relatively untested product are outweighed by the potential benefit. Using seizure-diaries to register seizure frequency, drug log and questionnaire to measure parent/patient quality of life and side effects will be assessed in each visit. Visits are: baseline, 4, 8, and 12 weeks visit. A 24 weeks visit (6 months) will be performed if the patient is stable on therapy during the 3 initial months and want to continue on the study for 3 more months. CBD will be administered as an adjunct to all current anti-epileptic therapies.
Status | Available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | All |
Age group | 5 Years to 19 Years |
Eligibility | Inclusion Criteria: Patients meeting the following criteria will be considered eligible for this study: - Age 5-19 years old - Documentation of a diagnosis of drug resistance epilepsy as evidenced by failure to control seizures despite appropriate trial of three or more anti-epileptic drugs at therapeutic doses. Some of these drugs include Brivaracetam, Carbamazepine, Clobazam, Clonazepam, Diazepam, Divalproex Sodium, Eslicarbazepine Acetate, Ethosuximide, Felbamate, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Oxcarbazepine, Perampanel, Phenobarbital, Phenytoin, Pregabalin, Rufinamide, Valproic Acid, Vigabatrin, Zonisamide. Documentation must include the diagnosis of epilepsy type or epilepsy syndrome (if possible), as well as the underlying case, when known. - Between 1-3 baseline anti-epileptic drugs at stable doses for a minimum of 4 weeks prior to enrollment. Vagus nerve stimulator, and dietary therapies do not count toward this parameter, but are not bases for exclusion. - Vagus nerve stimulator must be on stable settings for a minimum of 3 months. - A history of significant epilepsy severity and neurocognitive delays, specifically a baseline history of being nonverbal and non-ambulatory without assistance Exclusion Criteria: The patient may not enter the study if ANY of the following apply: - Patients with resectable epilepsy or syndromes where dietary or other therapy is first line will not be enrolled prior to attempting those therapies with failure OR parental refusal of said therapies. - Treatment with any artisanal preparation containing or possible containing CBD during the month before initiation of the study drug. - Allergy to CBD or any cannabinoid. - Unable to comply with study visits/requirements. - CBD is contraindicated in pregnancy and during breast-feeding. Female subjects who are pregnant or breastfeeding will be excluded from treatment with CBD. Patients of childbearing potential will be screened for pregnancy prior to enrollment and during the study if a potential for pregnancy arise. A blood pregnancy test will be used. Additionally, for patients of childbearing potential, enrollment criteria will require the use of highly effective contraception (e.g. double barrier, abstinence, or IUD) for the duration of treatment with CBD. Therefore, parent/guardian of female subjects must tell the investigator and consult an obstetrician or maternal-fetal specialist if the child become pregnant during the study. - Significant impaired hepatic function at screening as characterized by one of the following: i. Alanine aminotransferase [ALT] >5 × upper limit of normal (ULN) and total bilirubin (TBL) >2 × ULN ii. ALT or Aspartate aminotransferase (AST) >3 × ULN and either TBL >2 × ULN or international normalized ratio (INR) >1.5 - History or presence of alcohol or substance abuse - Use of other cannabis or CBD products |
Country | Name | City | State |
---|---|---|---|
United States | University of Mississippi Medical Center | Jackson | Mississippi |
Lead Sponsor | Collaborator |
---|---|
John |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04378075 -
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
|
Phase 2/Phase 3 | |
Recruiting |
NCT05928598 -
Goals for Epilepsy Clinic Visits Trial
|
N/A | |
Recruiting |
NCT05539287 -
Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy
|
Phase 2 | |
Not yet recruiting |
NCT04601974 -
Lentiviral Gene Therapy for Epilepsy
|
Phase 1/Phase 2 | |
Completed |
NCT02982824 -
Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy
|
N/A | |
Recruiting |
NCT05485558 -
the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy
|
Phase 2 | |
Not yet recruiting |
NCT04553354 -
Cortical Resections in Drug Resistant Epilepsy
|
||
Recruiting |
NCT04999046 -
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
|
N/A | |
Recruiting |
NCT04714996 -
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
|
Phase 2 | |
Recruiting |
NCT04839601 -
RNS System RESPONSE Study
|
N/A | |
Recruiting |
NCT06059157 -
Epileptogenic Network Visualisation With Advanced MRI
|
N/A | |
Recruiting |
NCT05947656 -
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
|
N/A | |
Recruiting |
NCT05393518 -
Electroclinical Correlation of Anxiety
|
N/A | |
Not yet recruiting |
NCT05555537 -
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
|
||
Completed |
NCT03419000 -
Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY
|
N/A | |
Enrolling by invitation |
NCT06341075 -
Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy
|
N/A | |
Not yet recruiting |
NCT05527093 -
Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05697614 -
The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
|
Phase 4 | |
Recruiting |
NCT06309251 -
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
|
||
Recruiting |
NCT06432907 -
StereoEEG Motor Neuronal Potentials Decoding
|
N/A |